Abstract
For patients with asthma, the dose/frequency of omalizumab is determined by bodyweight and pretreatment IgE levels. Since patients who fall outside the dosing table may be treated with omalizumab, we assessed respiratory-related patient-reported outcomes (Asthma Quality of Life Questionnaire [AQLQ]; mini Rhinoconjunctivitis Quality of Life Questionnaire [miniRQLQ]) stratified by where they fell on the omalizumab dosing table.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
